US Patent Issued to Horizon Therapeutics USA on Nov. 11 for "Reducing immunogenicity to pegloticase" (Illinois, Washington, Alaska Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,465,631, issued on Nov. 11, was assigned to Horizon Therapeutics USA Inc. (Deerfield, Ill.).

"Reducing immunogenicity to pegloticase" was invented by Jeffrey D. Kent (Deerfield, Ill.), Brian Lamoreaux (Deerfield, Ill.), John Botson (Anchorage, Alaska) and Jeff Peterson (Kirkland, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging th...